Cell News and Research

RSS

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.

5 Feb 2010

Scientists discover new technique to destroy individual diseased cells

Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions.

5 Feb 2010

ThermoGenesis announces distribution agreement with GE Healthcare for its AXP System

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, today announced a new enhanced distribution agreement with GE Healthcare, a unit of General Electric Company, for its AXP® AutoXpress ™ (AXP) System used in the processing of cord blood.

5 Feb 2010

Sequenom CMM launches SensiGene Fetal RHD Genotyping test for pregnant RhD negative women

Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S.

4 Feb 2010

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

4 Feb 2010

Dundee Centre to help set the pace for national and international progress in cancer research

Dundee today (Thursday) becomes Scotland's first link in a unique chain of Cancer Research UK Centres that are being launched across the UK. The launch of the Dundee Centre coincides with World Cancer Day.

4 Feb 2010

VaxGen-OXiGENE merger not approved

VaxGen, Inc. announced preliminary results of the vote from its special stockholder meeting held on February 3, 2010.

4 Feb 2010

First annual Translational Regenerative Medicine Forum in Winston-Salem

The Regenerative Medicine Foundation today announced the first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.

4 Feb 2010

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Antiviral drugs block influenza A viruses from reproducing and spreading by attaching to a site within a proton channel necessary for the virus to infect healthy cells, according to a research project led by Iowa State University's Mei Hong and published in the Feb. 4 issue of the journal Nature.

4 Feb 2010

Mapping of human genome modification during embryonic development

Scientists at The Genome Institute of Singapore (GIS) and The Scripps Research Institute (TSRI) led an international effort to build a map that shows in detail how the human genome is modified during embryonic development.

4 Feb 2010

Study sheds new light on cancer metastasis

Some cells are natural rule-breakers. Neural crest cells for example, not only migrate throughout the body during development (most cells are more selective in their wandering), they are also more developmentally flexible than their predecessors (a no-no for nearly all cell types).

4 Feb 2010

Scientists identify potential drug therapy target for malaria

Scientists at Washington University School of Medicine in St. Louis have identified a protein made by the malaria parasite that is essential to its ability to take over human red blood cells.

4 Feb 2010

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Fast growing Scottish biotech company Sistemic Ltd today announced that it had closed a series A funding round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund. The company will use the funding to further develop its proprietary SistemRNA compound-centric drug discovery technology. Using SistemRNA shortens the odds in drug discovery by enabling far more accurate prediction of potential drug indications, interactions and side effects.

4 Feb 2010

Type 1 diabetes: Regeneration exhibits potential as a possible cure

A hormone responsible for the body's stress response is also linked to the growth of insulin-producing cells in the pancreas, according to JDRF- funded researchers at the Salk Institute for Biological Studies in California. The findings are the latest advances to underscore the potential for regeneration as a key component of a possible cure for type 1 diabetes.

4 Feb 2010

Waiting for birth as effective as inducing labor for intrauterine growth restriction

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in Chicago, researchers will unveil findings that show that waiting for birth is as effective as inducing labor in cases of intrauterine growth restriction (IUGR).

4 Feb 2010

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.

4 Feb 2010

Cell News and Research

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Scientists discover new technique to destroy individual diseased cells

ThermoGenesis announces distribution agreement with GE Healthcare for its AXP System

Sequenom CMM launches SensiGene Fetal RHD Genotyping test for pregnant RhD negative women

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

Dundee Centre to help set the pace for national and international progress in cancer research

VaxGen-OXiGENE merger not approved

First annual Translational Regenerative Medicine Forum in Winston-Salem

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Mapping of human genome modification during embryonic development

Study sheds new light on cancer metastasis

Scientists identify potential drug therapy target for malaria

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Type 1 diabetes: Regeneration exhibits potential as a possible cure

Waiting for birth as effective as inducing labor for intrauterine growth restriction

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo